^
    Back
    Association details:
    Biomarker:SORT1 expression
    Cancer:Ovarian Cancer
    Drug:sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    TH1902 in Patients With Advanced Solid Tumors

    Excerpt:
    ...Histologically or cytologically confirmed TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, prostate cancer or other cancer known to express SORT1 that is refractory or resistant to standard therapy (replaces inclusion criterion #3)....
    Trial ID:
    NCT04706962
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Pharmaceutics
    Title:

    The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells

    Published date:
    09/09/2022
    Excerpt:
    Immunophenotyping of hTNBCSC and hOvCSC was performed by flow cytometry and confirmed the expression of SORT1...In vivo, using immunosuppressed nude mice xenografts, TH1902 significantly inhibited the growth of hTNBCSC and hOvCSC xenografts (~80% vs. ~35% for docetaxel) when administered weekly as intravenous bolus for three cycles at 15 mg/kg, a dose equivalent to the maximal tolerated dose of docetaxel.
    DOI:
    10.3390/pharmaceutics14091910